Vantaggiato, L.; Cameli, P.; Bergantini, L.; d’Alessandro, M.; Shaba, E.; Carleo, A.; Di Giuseppe, F.; Angelucci, S.; Sebastiani, G.; Dotta, F.;
et al. Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment. Biomedicines 2022, 10, 761.
https://doi.org/10.3390/biomedicines10040761
AMA Style
Vantaggiato L, Cameli P, Bergantini L, d’Alessandro M, Shaba E, Carleo A, Di Giuseppe F, Angelucci S, Sebastiani G, Dotta F,
et al. Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment. Biomedicines. 2022; 10(4):761.
https://doi.org/10.3390/biomedicines10040761
Chicago/Turabian Style
Vantaggiato, Lorenza, Paolo Cameli, Laura Bergantini, Miriana d’Alessandro, Enxhi Shaba, Alfonso Carleo, Fabrizio Di Giuseppe, Stefania Angelucci, Guido Sebastiani, Francesco Dotta,
and et al. 2022. "Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment" Biomedicines 10, no. 4: 761.
https://doi.org/10.3390/biomedicines10040761
APA Style
Vantaggiato, L., Cameli, P., Bergantini, L., d’Alessandro, M., Shaba, E., Carleo, A., Di Giuseppe, F., Angelucci, S., Sebastiani, G., Dotta, F., Bini, L., Bargagli, E., & Landi, C.
(2022). Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment. Biomedicines, 10(4), 761.
https://doi.org/10.3390/biomedicines10040761
